|
The Boston-based biotech is axing Phase II plans for its only clinical-stage asset, in a bid to maximise shareholder value.
|
 |
|
Xcellon Biologics will incorporate IntoCell’s OHPAS drug-linker system into its range of ADC development suites.
|
|
|
4D-150 delivers a sustained release of anti-vascular endothelial growth factor with one intravitreal injection.
|
|
|
Bayer and BI have reported broadly similar efficacy outcomes for sevabertinib and Hernexeos.
|
|
|
Sac-TMT will compete with two other TROP-2 targeted ADCs already approved: Gilead’s Trodelvy and AstraZeneca and Daiichi Sankyo’s Datroway.
|
|
|
Epioxa is a small molecule drug delivered as an eye drop that strengthens the cornea.
|
|
